Form 4: Replimune Group's Chief Medical Officer Receives Stock Options and Restricted Stock Units

Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., reports acquisition of stock options and restricted stock units.

Summary

• Konstantinos Xynos, the Chief Medical Officer of Replimune Group, Inc., filed a Form 4 on April 3, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of 45,000 shares of common stock issuable upon settlement of restricted stock units (RSUs).
• These RSUs vest over time, with 25% vesting on May 15, 2026, and the remainder vesting in three approximately equal annual installments until May 15, 2029, contingent upon continuous service.
• Xynos also acquired options to purchase 67,500 shares of common stock at an exercise price of $8.40.
• 25% of these options vest on April 1, 2026, with the remainder vesting in 36 approximately equal monthly installments thereafter.
• Following these transactions, Xynos beneficially owns 154,885 shares of Replimune Group, Inc. common stock and options for 67,500 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-to-positive event.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Industry Context

Stock option and RSU grants are common practices in the biotechnology industry to attract and retain key personnel, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in biotech companies typically include a mix of stock options and restricted stock units.
• The vesting schedules are fairly standard, designed to incentivize long-term commitment.
• The specific amounts and terms would be benchmarked against peer companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Replimune Group, Konstantinos Xynos, Chief Medical Officer, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Vesting